Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019721 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00019721: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00019721 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019721, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to compare the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have metastatic melanoma that has not responded to previous therapy.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL gp100 antigen
- BIOLOGICAL MART-1 antigen
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-04 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019721
The ClinicalTrials.gov registry entry for NCT00019721 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which aldesleukin is the first listed.
NCT00019721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019721 about?
NCT00019721 is a clinical study titled "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to compare th...
What is the current status of trial NCT00019721?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-04. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00019721?
The interventions under investigation include: aldesleukin (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), gp100 antigen (BIOLOGICAL), MART-1 antigen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00019721?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.